CClinicalTrials.gg
RecruitingNCT03538457Updated Aug 13, 2026

Bariatric Surgery and Pharmacokinetics of Paracetamol

An observational study in Obesity, Morbid, sponsored by Norwegian University of Science and Technology. Recruiting at 1 site in Norway. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Norwegian University of Science and Technology · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
12
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on paracetamol are investigated.

02

Conditions studied

  • Obesity, Morbid

Browse trials for

Keywords

  • Bariatric surgery
  • Gastrointestinal tract
  • Biological availability
  • Pharmacokinetics
  • Acetaminophen
03

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients referred for bariatric surgery (gastric bypass or sleeve gastrectomy)

Inclusion criteria

  • Preparing to undergo gastric bypass or sleeve gastrectomy in Central Norway
  • Being a Norwegian citizen

Exclusion criteria

Exclusion Criteria:

  • Having previously undergone resections in the GI-tract
04

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
12 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • DrugParacetamol

    Patients are tested for their normal prescription paracetamol medication

    Also known as: Acetaminophen, Acephen, Tylenol

05

What researchers measure

Primary outcomes

  1. Paracetamol concentration in blood serum (area under curve (AUC))

    Time frame: From baseline to 1 year postoperatively

06

Study locations

1 of 1 sites recruiting
  • St. Olavs University Hospital
    Trondheim, Norway
    • Magnus Strømmen, MSc · Contact
    Recruiting
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03538457
Lead sponsor
Norwegian University of Science and Technology
Collaborators
St. Olavs Hospital, Volvat Medisinsk Senter Stokkan, Namsos Hospital, Alesund Hospital
Responsible party
Sponsor
First posted
May 29, 2018
Start date
Nov 2, 2016
Primary completion
Oct 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Aug 13, 2026

Study contacts

Magnus Strømmen, MSc
Contact
magnus.strommen@stolav.no
0047 72829970
Magnus Strømmen, MSc
principal investigator · St. Olavs Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion